Latest News and Press Releases

New York, USA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | DelveInsight Atrial...

Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Market Size, Share & Trends Analysis Report by Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment), by...

CoreMap, Inc. Receives U.S. FDA Investigational Device Exemption (IDE) Approval for INvENI Map-Guided AF Ablation Study

New York, United States, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Pharmaceuticals known as atrial fibrillation (AF) medicines are employed in the treatment of atrial fibrillation, a prevalent cardiac...

CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...

Rockville, MD, Oct. 02, 2024 (GLOBE NEWSWIRE) -- As per a recently published industry report by Fact.MR, the global single-lead ECG monitor market is estimated to reach a valuation of US$ 669...

Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 01, 2024 (GLOBE NEWSWIRE) -- The global cardiac mapping market stood at US$ 3 billion in 2023, and the global market is...

75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...